Under pressure, Biogen outlines ambitious diversity goals for Aduhelm study — but the Medicare fight is still on

Biogen, facing renewed criticism for a lack of diversity in its Alzheimer’s clinical trials, announced on Thursday a new commitment: At least 18% of the participants in the FDA-mandated confirmatory study for its controversial drug Aduhelm will be Black or Latinx.